412923-42-3

Basic information

• Product Name: 6-BROMO-4-CHLORO-2-PHENYL-QUINAZOLINE
• Synonyms: 6-BROMO-4-CHLORO-2-PHENYL-QUINAZOLINE;QUINAZOLINE, 6-BROMO-4-CHLORO-2-PHENYL-
• CAS NO: 412923-42-3
• Molecular Formula: C₁₄H₈BrClN₂
• Molecular Weight: 319.58
• Mol File: 412923-42-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 6-BROMO-4-CHLORO-2-PHENYL-QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-CHLORO-2-PHENYL-QUINAZOLINE(412923-42-3)
• EPA Substance Registry System: 6-BROMO-4-CHLORO-2-PHENYL-QUINAZOLINE(412923-42-3)

Safety Data

• Hazard Codes: T
• Statements: 25-41
• Safety Statements: 26-39-45
• Hazardous Substances Data: 412923-42-3(Hazardous Substances Data)

Usage

General Description

6-Bromo-4-chloro-2-phenyl-quinazoline is a synthetic organic compound characterized by its bromo, chloro and phenyl moieties. It falls under the chemical class of quinazolines, a class of organic compounds characterized by a two-ring system consisting of a benzene ring fused to a pyrimidine ring. 6-BROMO-4-CHLORO-2-PHENYL-QUINAZOLINE, along with other quinazolines, are often used in the field of medicinal chemistry for their pharmacological activities. Specific properties or toxicity of this particular quinazoline (6-Bromo-4-chloro-2-phenyl-quinazoline) are not extensively documented in scientific literature, hence, its specific applications or hazards remain largely unknown. However, as a chemical, precautions should be taken when handling it.

InChI:InChI=1S/C14H8BrClN2/c15-10-6-7-12-11(8-10)13(16)18-14(17-12)9-4-2-1-3-5-9/h1-8H

Upstream product

• 27398-50-1 6-bromo-2-phenyl-3H,4H-quinazolin-4-one 
• 27398-50-1 6-bromo-2-phenylquinazolin-4-one 
• 66387-70-0 6-bromo-2-phenyl-4H-benzo[2,3-d]-1,3-oxazin-4-one 
• 639482-27-2 2-benzamido-5-bromobenzamide 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 98-88-4 benzoyl chloride 
• 16313-66-9 5-bromoanthranilamide 
• 28144-70-9 anthranilic acid amide 

Downstream Products

• 1028318-50-4 C₁₇H₁₄BrN₃O₂ 
• 1028318-56-0 2-(6-bromo-2-phenylquinazolin-4-ylamino)-3-methylpentanoic acid 
• 1028318-53-7 C₂₃H₁₈BrN₃O₂ 
• 1028318-47-9 C₁₆H₁₂BrN₃O₂ 
• 1028318-59-3 C₂₅H₁₉BrN₄O₂ 
• 1086462-47-6 C₂₁H₁₄BrN₃O₂ 
• 1086462-61-4 C₂₂H₁₄BrN₅O₂ 
• 1086462-50-1 C₂₂H₁₆BrN₃O₂ 
• 1086462-65-8 C₂₂H₁₄BrN₅OS 
• 1204389-84-3 N-hexadecyl-N(6-bromo-2-phenyl-4-quinazolinyl)amine 
• 1204389-83-2 N-decyl-N(6-bromo-2-phenyl-4-quinazolinyl)amine 
• 1136496-38-2 6-bromo-4-(4-methyl-1-piperazinyl)-2-phenylquinazoline 
• 1137462-74-8 C₂₀H₂₀BrN₃ 
• 1257346-05-6 C₂₅H₂₂BrN₃ 

Relevant articles and documents

Efficient N-arylation of 4-chloroquinazolines en route to novel 4-anilinoquinazolines as potential anticancer agents

Microwave-mediated N-arylation of 4-chloroquinazolines in THF/H2O rapidly and efficiently afforded a library of novel 6-halo-2- phenyl-substituted 4-anilinoquinazolines. The methodology was compatible with numerous ortho-, meta-, and para-substituted N-methylanilines as well as substituted anilines and furnished the corresponding 4-anilinoquinazolines in good yields. Preliminary screening of the synthesized compounds against tumor cells (HCT-116 and T98G) showed promising antiproliferative properties.

Synthesis and characterization of novel quinazoline-substituted 1,3,4-thiadiazolium-5-thiolates

Novel 3-[4-(6-bromo-4-oxo-2-phenylquinazolin-3(4H)-yl)benzoyl]-2- substituted-1,3,4-thiazolium-5-thiolate 7(a-j) and 3-{4-[(6-bromo-2- phenylquinazolin-4-yl)amino] benzoyl}-2-substituted-1,3,4-thiadiazolium-5- thiolate 12(a-j) were synthesized from 6-brom

Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives

Two series of some new 2,4,6-trisubstituted-quinazoline derivatives were prepared and screened for their analgesic, anti-inflammatory activity and acute toxicity. Four compounds were more potent analgesic agents than the reference drug Indomethacin and thirteen compounds showed significant anti-inflammatory activity. Seven compounds showed combined ability to inhibit both pain and inflammation. Compounds tested for acute toxicity showed no toxic symptoms or mortality rates 24 h post-administration implying their good safety margin.